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Objectives: To identify and to characterize small-molecule inhibitors that target the subunit polymerization of
the type 1 pilus assembly in uropathogenic Escherichia coli (UPEC).
Methods: Using an SDS–PAGE-based assay, in silico pre-filtered small-molecule compounds were screened for
specific inhibitory activity against the critical subunit polymerization step of the chaperone–usher pathway
during pilus biogenesis. The biological activity of one of the compounds was validated in assays monitoring
UPEC type 1 pilus biogenesis, type 1 pilus-dependent biofilm formation and adherence to human bladder epithelial
cells. The time dependence of the in vivo inhibitory activity and the overall effect of the compound on UPEC growth
were determined.
Results: N-(4-chloro-phenyl)-2-{5-[4-(pyrrolidine-1-sulfonyl)-phenyl]-[1,3,4]oxadiazol-2-yl sulfanyl}-acetamide
(AL1) inhibited invitropilus subunit polymerization. In bacterial cultures, AL1 disrupted UPECtype 1 pilus biogenesis
and pilus-dependent biofilm formation, and resulted in the reduction of bacterial adherence to human bladder
epithelial cells, without affecting bacterial cell growth. Bacterial exposure to the inhibitor led to an almost instant-
aneous loss of type 1 pili.
Conclusions:We have identified and characterized a small molecule that interferes with the assembly of type 1 pili.
The molecule targets the polymerization step during the subunit incorporation cycle of the chaperone–usher
pathway. Our discovery provides new insight into the design and development of novel anti-virulence therapies
targeting key virulence factors of bacterial pathogens.
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Introduction
For many pathogenic bacteria, the contact interface with their
hosts is formed by proteinaceous hair-like cell surface appendages
termed pili or fimbriae. In Gram-negative bacteria, these structures
are assembled through a number of dedicated secretion pathways
that play a crucial role in mediating bacterial traits associated with
virulence, including host cell adherence and/or invasion, biofilm
formation and transportation of DNA or proteins across mem-
branes.1 The prospect of disrupting the biogenesis or function
of these nanomachineries has garnered increasing interest as
an anti-virulence approach against pathogenic bacteria. The
growing knowledge of the structural basis and molecular
processes steering the assembly and secretion of these virulence
structures and their prevalence in clinically relevant pathogens
render them a promising target for development of novel
therapeutic agents.2 – 4
Uropathogenic Escherichia coli (UPEC) is the major aetiological
agent of urinary tract infections (UTIs) and it is estimated to
affect 150 million individuals globally per annum.5 The use of avail-
able antibiotics has led to significant improvements in the man-
agement of UTIs; however, recurrent infections6 and an
increasing resistance to conventional antibiotics, as exemplified
by the recent pandemic of the multidrug-resistant UPEC strain
ST131,7 – 9 are a cause of major concern. UPEC also form a burden
in hospital or nursery wards, representing up to 30% of nosocomial
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infections, especially in patients with urinary catheters.10 The indis-
pensable steps in the onset and persistence of UPEC infections are
theattachmentandinvasionofbladderepithelialcellsandtheestab-
lishment of biofilm-like intracellular bacterial communities.11–13
These steps are crucially dependent on the presence of type 1 pili
and previous efforts to impair their assembly or adhesive function
have yielded several promising antagonists (reviewed in Lo et al.,4
Cegelski et al.14 and Waksman and Hultgren15). Here, we describe
the identification and characterization of a small-molecule inhibitor
that impedes the biogenesis of type 1 pili by targeting subunit poly-
merization in an early assembly step.
Type 1 pili are assembled by a highly conserved biosynthetic
assembly mechanism termed the chaperone–usher pathway.
Chaperone–usher pathways are responsible for the biogenesis of
a diverse arsenal of virulence-associated cell surface organelles
present in a myriad of pathogenic g-proteobacteria.1,16 Besides
the adhesin and structural pilus subunits, theycomprise two acces-
sory components: a periplasmic chaperone captures nascent sub-
units as they emerge from the inner membrane translocon and
shuttles them to an outer membrane assembly platform, the
usher, where pilus subunits are incorporated into the base of the
growing fibre and subsequently translocate across the outer mem-
brane.17 – 19 Chaperone–usher pilus subunits are characterized by
an incomplete immunoglobulin (Ig) fold lacking the C-terminal
b-strand, and by the presence of a disordered extension of
10–20 residues at the N-terminus.20,21 In the periplasm, pilus sub-
units are stabilized by the chaperone, which donates an extendedb
strand (strand G1) to complement the missing structural informa-
tion in the subunit Ig fold.20,21 At the usher, subunits undergo non-
covalent polymerization through a similar fold complementation
mechanism, now involving the N-terminal extension peptide
(Nte) of the newly incoming pilus subunit (Figure S1, available as
Supplementary data at JAC Online). These Nte sequences contain
a conserved motif of alternating hydrophobic residues termed
‘P2–P5 residues’ that make knobs into hole-packing interactions
with the equivalent hydrophobic pockets in the acceptor groove
of the pilus subunit (Figure 1a and b). In the chaperone–subunit
interaction, the G1 strand occupies pockets P1–P4 and leaves P5
accessible to the solvent (Figure 1a and b). During subunit polymer-
ization, the chaperone G1 donor strand bound to the subunit at the
base of the pilus is exchanged for the Nte of the newly recruited
chaperone:subunit complex, a process called ‘donor strand ex-
change’ (DSE).22 DSE occurs in a concerted ‘zip-in zip-out’ mechan-
ism that involves the formation of a transient ternary complex
between the chaperone:subunit complex and the incoming
Nte.23 DSE ternary complex formation is initiated by the docking
of the Nte P5 residue to the P5 pocket on the acceptor chaperone:-
subunit complex.23
The adhesive subunit, FimH, constitutes the first subunit to be
incorporated, is present in a single copy and is crucial for the activa-
tion of the FimD usher for pilus assembly.24 In addition, genetic in-
activation of FimG and/or FimF, the subunits succeeding FimH and
forming the link between the adhesin and the FimA pilus shaft,
leads to polymerization arrest and the accumulation of FimD:-
FimC:FimH complexes unable to promote mannose-sensitive
haemagglutination.25 Hence, we speculated that the chemical in-
hibition of the DSE reaction between FimH and FimG would prevent
FimG incorporation into the pilus as well as that of downstream
subunits. We reasoned that chemical compounds that are able
to competitively interact with the P5 pocket would serve as pilus
polymerization inhibitors.
Here, we performed structure-based in silico screens of chem-
ical libraries to derive a filtered set of compounds with predicted
complementarity to the FimC:FimH P5 pocket area, which were
subsequently tested for in vitroDSE inhibition. Using this approach,
we have identified a compound that is able to inhibit the DSE reac-
tion between FimH and FimG Nte in a concentration-dependent
manner. Bacteria exposed to the inhibitor were found to be
devoid of type 1 pili or surface-exposed FimH. We further show
that the inhibitor impedes the type 1 pilus-dependent virulence
traits critical for UPEC pathogenesis, including biofilm formation
and adherence to human bladder epithelial cells. Strikingly, the dis-
ruption of UPEC type 1 pili appears to occur almost instantaneously
upon addition of the compound, suggesting that the activity may
not be restricted to de novo synthesis, but extends to pre-formed
pili. To the best of our knowledge, this is the first report of a small-
compound molecule that specifically targets the polymerization
step in the pilus subunit incorporation cycle. Collectively, this
study provides the basis for the design and development of
compounds for therapeutic intervention against other clinically
significant pathogens.
Materials and methods
Bacterial strains
Uropathogenic E. coli UTI89, UTI89 DfimA–H and E. coli BL21 (DE3) are
described in Table S1 (available as Supplementary data at JAC Online).
Construction, expression and purification of FimChis:FimH
To facilitate the cloning of fimH and fimC for co-expression, the MultiSite
Gatewayw Three-Fragment Vector Construction Kit (Invitrogen) was used.
The full coding sequence of fimC with a C-terminal His tag was amplified
from pETS100026 using primers FimCf and FimCr (Table S1, available as Sup-
plementary data at JACOnline) and cloned into pDONRP4-P1R donor vector
via attB/attP recombination, resulting in pKVWc1. The full coding sequence
of fimH was amplified using FimH3 and FimH7 primers and cloned into
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Figure 1. Identification of pilus polymerization inhibitors. Structure (a) and
schematic representation (b) of the FimH pilin domain (shown as grey
molecular surface, encompassing residues 158 to 279 of PDB:1ZE3) in
complex with the FimC F1–G1 strands (green) or FimG Nte peptide (blue;
taken from PDB:3JWN). The P5 pocket is labelled and the P5 binding residue
(Val11) is shown as sticks. (b) P1 to P5 pockets are shown as white ovals and
the interacting residues in the FimC F1 strand or FimGNte are labelled.
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pDONR221 via BP recombination, yielding pENT53. To monitor the protein
complex yield, the green fluorescent protein gene gfp+27 was amplified
from pWH1012gfp+ using gfp7 and gfp8 primers and cloned into
pDONRP2R-P3, yielding pENT105. Subsequently, pKVWc1, pENT53 and
pENT105 underwent attL/attR recombination in the presence of
pDEST22a to generate pKVWe1 expression vector. The pDEST22a was
derived from pET22b (Novagen) digested with XbaI and EcoRI and followed
by a fill-in reaction to generate blunt ends. The attR4-ccdB-CmI-attR3 cas-
sette was amplified from pDEST R4–R3 using primers FP24 and RP24 and
ligated into the linearized pET22b, resulting in pDEST22a.
E. coli BL21 (DE3) harbouring pKVWe1 was grown at 378C in M9 minimal
medium supplemented with 0.4% glucose, 20 mM MgCl2, 100 mg/mL
ampicillin and 1% (v/v) vitamin solution. Cells were induced at an OD600
of 1 with 1 mM IPTG at 378C (where OD stands for optical density). Periplas-
mic extraction of cells incubated overnight was carried out. The FimChis:-
FimH complex was purified using a Ni-NTA column (Qiagen). The complex
was eluted with 200 mM imidazole in 20 mM Tris–HCl, pH 8.8/250 mM
NaCl buffer. Fractions containing the FimChis:FimH complex as judged by
SDS–PAGE were pooled and dialysed against 20 mM MES, pH 6/10 mM
NaCl overnight at 48C. The final polishing step was done using a HiTrap SP
FF column (GE Healthcare) at room temperature and subjected to
10 mM–1 M NaCl gradient elution. FimChis:FimH was eluted at 400 mM
NaCl and dialysed against 20 mM Tris, pH 8.8/10 mM NaCl overnight at 48C.
Virtual screening
Two docking strategies were employed. First, the docking area was limited
to the P5 pocket as found in the chaperone:subunit complex in PDB:1ze3
(Figure S2a, available as Supplementary data at JAC Online). Second, com-
pounds were allowed to dock in the more extended donor strand acceptor
groove (Figure S2b, available as Supplementary data at JAC Online), repre-
senting a binding mode in which they induce full or local displacement of
the chaperone donor strand. In practice, FimC (chain C in PDB:1ze3) was
removed from the crystal structure to create the extended groove. FimC
was omitted from the complex and a hydrophobic anchor was placed at
the P5 site to allow for docking to the full binding groove extending into
P3 and P4 pockets (Figure S2b, available as Supplementary data at JAC
Online). The anchor was used to force binding near the P5 site.
A set of 72000 small molecules was assembled from an Asinex diverse
library28 (30000 compounds) and a Chembridge CNS/Novacore/Diverset
structurally diverse library (42000 compounds) and was utilized for the
in silico screen. These compounds are compliant with Lipinski’s rule-of-five
criteria and considered drug-like.28,29Docking was performed in two stages.
FRED wasused for thewholesetof the dataasthis is avery fast program. Ten
energy-minimized conformers for each chemical compound were gener-
ated using MOE30 as initial structures for FRED.31 Chemscore32 was used
as scoring function in FRED. The best 5000 hits from FRED were docked
again using GOLD.33 GOLD generates multiple low-energy conformers on
the fly. The GOLD docking was performed using GOLD’s genetic algorithm
(GA) with scoring function GoldScore.34
In vitro DSE inhibition assay
FimG:FimH DSE reactions were initiated by addition of 50 mM FimG
N-terminal extension peptide (FimGNte: ADVTITVNGKVVAKP-amide) to
2 mM FimChis:FimH complex in 100 mM Tris–HCl, pH 8.8/20 mM NaCl
buffer and incubated for 12 h at 378C. To screen for DSE inhibitors, DSE
assays were performed in the presence of the pre-selected compounds at
a final concentration of 500 mM each. The DSE reactions were then
loaded onto SDS–PAGE. The Coomassie-stained gels were scanned using
Bio-Rad Quantity Onew Chemi Doc XRS with automated sequential time
exposures. The intensity of the bands corresponding to FimChis, FimH
(the DSE substrate) and the SDS-resistant FimH:FimGNte complex (DSE
product) (Figure 2a) was quantified using Bio-Rad Quantity Onew analysis
software as a function of volume of pixels (intensity/mm2). The total inten-
sity within a defined border around the bands without overlapping nearby
bands was measured using the Volume Rectangle Tool. DSE completion
was calculated by the following equation: adjusted volume of pixels
(FimH:FimGNte)/adjusted volume of pixels (FimC+FimH+FimH:FimGNte).
The screening hit N-(4-chloro-phenyl)-2-{5-[4-(pyrrolidine-1-sulfonyl)-
phenyl]-[1,3,4]oxadiazol-2-yl sulfanyl}-acetamide (AL1) was re-ordered
from Asinex Corporation (ASN 03798371) at ≥97% purity (HPLC) and
synthesized in house (see additional methods, available as Supplementary
data at JAC Online) in order to confirm the chemical identity of the
biologically active compound.
Further DSE assays were performed in the presence of the hit compound
at concentrations ranging from 0.001 to 2 mM in 20% (v/v) DMSO to deter-
mine the IC50 values. DSE completion for compound-treated samples was
normalized over that of the non-treated control and plotted as a function of
compound concentration. The IC50 values were calculated by non-linear
regression analysis using GraphPad Prism. DMSO(20% v/v) wasthe negative
control.
Biofilm formation assay
Static biofilm formation was assayed as described by O’Toole and Kolter.35
Briefly, an overnight culture of UPECwas diluted 1/1000 with fresh Lysogeny
broth (LB) supplemented with compound and incubated in a 96-well micro-
titre plate at room temperature for 48 h. Wells were then washed twicewith
PBS and stained with 0.1% (w/v) crystal violet. Following two PBS washes,
biofilm-adsorbed crystal violet was extracted in 150 mL of ethanol and
quantified by absorbance at 595 nm. Absorbance measurements were
background corrected and are presented as the percentage of biofilm
formation following normalization to non-compound-treated UTI89 or
UTI89_LON36 cultures. The IC50 values and 95% CIs were calculated from
the concentration–response curves by non-linear regression analysis
using GraphPad Prism (a Hill slope of21.4).
ELISAwith anti-FimH antibody
Bacterial strains were grown in LB in the presence of 50 and 200 mM AL1 at
room temperature for 48 h. For FimH detection by whole-cell ELISA (WCE),
Nunc MaxiSorpTM flat-bottom 96-well plates (eBioscience) were coated
with bacteria washed in PBS. The OD600 of each well was measured and
plates were incubated at room temperature for 2 h. The wells were
washed twice in PBS and blocked with 1% BSA for 30 min. The presence
of type 1 pili was detected using a rabbit polyclonal anti-FimH antibody fol-
lowed by alkaline phosphate-conjugated goat anti-rabbit IgG (Sigma). The
reaction was developed in the presence of 5-bromo-4-chloro-3-indolyl-
phosphate/nitro blue tetrazolium substrate (Roche) and absorbance was
read at 405 nm.
Electron microscopy visualization of bacterial piliation
Treated and non-treated samples at room temperature for 48 h were fixed
with 1% (v/v) paraformaldehyde and stained with 0.5% (w/v) uranyl
acetate for visualization by electron microscopy (120 kV Jeol) in order to
quantify the amount of piliated versus non-piliated bacterial cells in each
sample. One hundred randomly chosen bacterial cells were counted for
each sample.
Pilus dislocation assays
Overnight bacterial cultures were diluted 1000-fold with fresh LB medium
and grown to an OD600 of 0.5 at 378C. Bacteria were then treated with
200 mM of compound. Cultures were sampled at 1, 30 and 60 min after
addition of compound or 1% DMSO for control samples. Samples were
washed and suspended in PBS at an OD600 of 0.1. WCE was performed
Curtailing bacterial virulence by pilus biogenesis inhibition
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using anti-FimH antibody to detect the presence of type 1 pili as described
above.
Yeast agglutination assays
Yeast agglutination was assayed in 96-well U-bottom microtitre plates by
mixing 35 mL of a 0.1 OD600 bacterial suspension sampled from cultures
at 1, 30 and 60 min after addition of compound (200 mM) or 1% DMSO
(control), with 10 mL of 2% (w/v) baker’s yeast suspended in 20 mM
sodium phosphate, pH 7.5/150 mM NaCl buffer. Following 5 min of incuba-
tion, yeast agglutination was visualized using a Moticam 2000 camera. The
agglutination titre represents the maximum serial dilution of the 0.1 OD600
bacterial suspension that still gives yeast agglutination.
Human urothelial cell adherence assay
The adhesion of compound-treated UTI89 to human urinary bladder epi-
thelial cell line 5637 (ATCC HTB-9) was assessed using the protocol
described by Wellens et al.37 Briefly, bacteria were grown in the presence
or absence of 200 mM of compound at room temperature for 48 h. Bacteria
were washed and suspended in PBS to an OD600 of 0.5. A total of 10
6 to 107
bacteria were added to each well of a 24-well plate (Falcon BD) containing a
confluent culture of bladder cells. Plates were shaken gently at room tem-
perature for 15 min to allow binding of the bacteria to the bladder cells. Un-
attached bacterial cells were removed by five washes in PBS. Bladder cell
lysis and detachment from culture plates was induced by incubation with
0.25% (w/v) trypsin/2 mM EDTA for 15 min and then terminated byaddition
of 10% fetal calf serum. Bacterial cfu in the bladdercells lysates were deter-
mined by 10-fold serial dilutions in PBS, plated onto LB agar plates. UTI89
DfimA–H and UTI89 grown in the presence of 1% (v/v) DMSO were used
as controls.
Pilus fate assays
To assess the effect of AL1 on pilus quaternarystructure, type 1 pili were iso-
lated from UTI89_LON by heat extraction and MgCl2 precipitation as
described by Brinton.38 Briefly, overnight bacterial cultures were diluted
1000-fold with fresh LB medium to a total of 8 L and grown to an OD600
of 1 at 378C. Bacterial cells were washed twice and suspended in PBS at
48C. Cell suspensions were heat shocked at 658C for 30 min. The cells
were pelleted and MgCl2 was added to the collected supernatant to a
final concentration of 0.1 M and incubated for at least 1 h at 48C to aggre-
gate the type 1 pili. The mixture was spun down and the precipitated pili
were resuspended in deionized water. Pili were treated with 200 and
500 mM AL1 for 5 min. The MgCl2-precipitated supernatant of heat-shocked
UTI89Dfimcells was usedas negative control. Boiled (5 min, 958C) and non-
boiled samples (in 1×NuPagew LDS Sample Buffer) were then resolved on
SDS–PAGE gels and transferred onto polyvinylidene difluoride membrane
using a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad Laboratories)
at 100 V for 1 h. Blots were probed with rabbit polyclonal antibody
against FimC:FimH complex (this study) followed by alkaline phosphatase-
conjugated goat anti-rabbit IgG (Sigma).
To determine the effect of AL1 on mature type 1 pili present on the bac-
terial surface, a total of 300 mL of UTI89_LON culture was grown to an
OD600 of 1 at 378C. The cells were washed twice and suspended in 4 mL
of PBS. A total of 200 mM compound was added to the cell suspension
and incubated for 1 min. The cells were removed from the suspension by
20 min of centrifugation at 10000 g. MgCl2 was added to the collected
supernatant to a final concentration of 0.1 M and incubated for at least
1 h at 48C before ultracentrifugation at 20000 g. Pellets were suspended
in deionized water to a volume that was scaled according to the total
volume of culture grown for a direct comparison with the above type 1
pilus isolation experiment. Western blot analysis was performed as
described above. Western blots were scanned using Bio-Rad Quantity
Onew Chemi Doc XRS. The intensity of the bands was then quantified
using Image Studio Lite software (LI-COR Biosciences) and expressed as
sum pixel intensity values within a defined border minus background
pixel intensity. The ratio of FimC to FimH for the different pilus isolates
was normalized against the ratio of FimChis to FimH for the purified
FimChis: FimH complex, since the latter is known to represent FimC and
FimH equimolar concentration.
Statistical analysis
Data were expressed as the sample mean+SEM. The difference between
two samples was assessed by two-tailed unpaired Student’s t-test, with
n indicated for each experiment (a is taken as 0.05). Individual experiments
were performed on different days, using independent starter cultures.
In each experiment, multiple samples were analysed or measured as
indicated.
Results and discussion
Structure-based in silico screening
To achieve more focused screening, chemical screening libraries
were pre-filtered using structure-based in silico docking with the
presupposition that compounds that have the potential to bind
to the P5 pocket would disrupt DSE. In the structure of the usher-
bound FimC:FimH complex (PDB:1ZE3),39 the P5 pocket forms a
hydrophobic, solvent-exposed pocket with approximate dimen-
sions of 8 A˚ long×7 A˚ wide×7 A˚ deep (Figures 1a and S2a and b,
available as Supplementary data at JACOnline). For virtual screen-
ing, two binding hypotheses were used. First, the docking area was
limited to the P5 pocket as found in the chaperone:subunit
complex; second, compounds were allowed to dock in the more
extended donor-strand acceptor groove, representing a binding
mode in which they induced full or local displacement of the chap-
erone donor strand (Figure S2a and b, available as Supplementary
data at JACOnline). For initial virtual screening, 72000 diverse com-
mercial compounds (see the Materials and methods section) that
have rule-of-five properties were used. Ten energy-minimized con-
formers for each chemical compound were generated using
MOE.30 Docking was performed with FRED31 and GOLD.33
DSE mechanism as the target for AL1 inhibition of pilus
subunit polymerization
To screen for type 1 pilus DSE inhibitors weemployed an SDS–PAGE-
based assay that monitored the formation of an SDS-stable
complex between FimH and the FimG Nte (Figure 2a; see the Mate-
rials and methods section). The 2000 compounds that scored most
favourably both in FRED and GOLD were taken through to in vitro
screening in the FimG:FimH DSE assay at 500 mM final concentra-
tion, each being incubated for 12 h at 378C. We identified 20 com-
pounds that resulted in a .50% reduction in FimG:FimH complex
formation under the screening conditions employed (data not
shown), amounting to a hit rate of 1% in the in silico-filtered
library. Of these, the most potent hit, AL1 (Figure 2b), was taken
forward for detailed characterization. DSE reactions of FimC:FimH
and FimG Nte were carried out in the presence of AL1 at various
concentrations, and showed that the compound exhibited a
concentration-dependent inhibition of DSE product formation,
with an IC50 value of 286 mM (95% CI 192–425 mM; R
2¼0.94)
(Figures 2c and S3, available as Supplementary data at JACOnline).
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Inhibition of type 1 pilus-dependent biofilm formation
In order to verify that the in vitro inhibition of FimG:FimH DSE
translates into in vivo inhibition of pilus formation, UPEC strain
UTI89, a cystitis isolate, was grown in presence of AL1 for 48 h at
room temperature and type 1 pilus formation was monitored using
a type 1 pilus-dependent biofilm formation assay.40,41 AL1 had no
adverse effects on bacterial growth in rich media (Figure S4b, avail-
able as Supplementary data at JACOnline) and inhibited type 1 pilus-
dependentbiofilm formation of UTI89 in aconcentration-dependent
manner (Figure 3a). Under the conditions tested, AL1 inhibited
UTI89 biofilm formation with an IC50 of 37 mM (95% CI 29–47 mM;
R2¼0.98; n¼3) (Figure 3a). For comparison we assessed the effect
of AL1 on the biofilm formation of a UTI89 mutant strain that con-
stitutively expresses type 1 pili (UTI89_LON36) under the same
growth conditions. AL1 inhibited UTI89_LON biofilm formation in a
concentration-dependent manner with an IC50 of 78 mM (95% CI
70–87 mM; R2¼0.97; n¼3) (Figure S4c, available as Supplementary
data at JAC Online).
In order to confirm that AL1 was responsible for the biological
activity found in commercially available sources, AL1 was synthe-
sized in house (see additional methods and Figure S5, available as
Supplementary data at JAC Online). In-house-synthesized AL1
showed IC50 values of 46 mM (95% CI 35–61 mM; R
2¼0.98;
n¼3) (AL1*; Figure 3a), closely matching those found for the com-
mercially available material. Thus, AL1 is responsible for the bio-
logical activity and appears to reach its target efficiently in
UTI89 periplasm. The mid-inhibitory concentrations for biofilm
formation were 6-fold lower compared with that of the in vitro
DSE assay. In vivo, FimG:FimH DSE is catalysed by the FimD usher
and occurs on a sub-minute timescale.42 In contrast, in vitro, the
non-catalysed DSE reaction requires a 25-fold excess of FimG
Nte in order to reach completion over a time scale of 12 h. This
excess of FimG Nte likely explains the higher IC50 values observed
in the DSE assay.
AL1 disrupts type 1 pilus formation in vivo
To confirm that the biofilm-deficient phenotype stems from the
loss of type 1 pili, the presence of surface-exposed FimH and type
1 pili on UTI89 grown in the presence of AL1 for 48 h at room tem-
perature was analysed by negative stain electron microscopy and
anti-FimH WCE (Figure 3b). WCE revealed that, compared with
DMSO-treated controls, UTI89 grown in the presence of 50 or
200 mM AL1 reduced surface-exposed FimH by85% and 97%, re-
spectively (P¼0.0003 andP¼0.0002, respectively,n¼2 independ-
ent experiments, each carried out in triplicate). Representative
electron micrographs showed peritrichous piliation of bacteria in
DMSO (control), whereas treatment with 50 or 200 mM AL1
resulted in non-piliated and sparsely piliated bacteria, respectively
(Figures 3c and S6, available as Supplementary data at JACOnline).
Moreover, the few pili that were present on the bacteria at 50 mM
AL1 were aberrantly long (Figure 3c). A similar phenotype is
observed in fimHmutant strains, where the accumulated periplas-
mic pool of FimA pilus subunits is directed to those fewpilus assem-
bly platforms in the outer membrane that non-specifically become
activated for pilus assembly in the absence of FimH.43 This leads to
non-physiologically long pili that have an increased tendency to
break under shear stress.
AL1 attenuates UPEC adherence to human bladder cells
The lackof type 1 pili renders UPECavirulent byabrogating its ability
to colonize and invade during earlyevents of infection.44 UTI89 cul-
tured in the presence of 200 mM AL1 for 48 h at room temperature
exhibited a 74% reduction in the ability to bind to human bladder
cells compared with non-treated bacteria (P¼0.0003, n¼2 inde-
pendent experiments, each carried out in triplicate) (Figure 4).
Under the same conditions, bladder cell binding of UTI89 Dfim
was reduced by 84% relative to wild-type.
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Figure 2. Inhibition of in vitroDSE. (a) SDS–PAGE showing FimC:FimH DSE with FimGNte after a 12 h incubation. FimH:FimGNte forms an SDS-stable complex
that shows a mobility shift compared with FimH. (b) Structure of AL1. (c) Concentration–response curve for in vitro FimC:FimH–FimGNte DSE in the presence
of AL1 (0.001–2 mM). DSE progression as a function of AL1 concentration, presented as adjusted volume of pixels of the DSE product (FimH:FimGNte) over
the adjusted volume of pixels of the total protein (FimC+FimH+FimH:FimGNte) and normalized over non-treated DSE.
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AL1 causes a rapid decrease in surface-exposed type 1 pili
In each of the above experiments, AL1 was present throughout
bacterial growth. To determine the timepoint at which AL1
becomes active, UTI89 was cultured in rich medium and exposed
to 200 mM AL1 during the exponential growth phase. Cells were
harvested at 1, 30 and 60 min post-treatment and assayed for
FimH surface exposure using ELISA and type 1 pilus counts by elec-
tron microscopic visualization (Figure 5a and b). Based on a model
in which AL1 exclusively acts on nascent pili, we predicted levels of
surface-exposed FimH to drop by 50% per generation time
(20 min). However, we found that surface-exposed FimH was
reduced to background levels within 1 min after the addition of
AL1 (Figure 5a). Indeed, electron microscopic inspection revealed
that the AL1-treated cells had lost their type 1 pili within 1 min fol-
lowing exposure to the compound (Figure 5b). In AL1-treated cul-
tures the level of piliated bacteria decreased to 2%, whilst
DMSO-treated controls maintained near wild-type levels of pili
(Figure 5b). The rapid loss of type 1 pili upon AL1 treatment was
corroborated in a yeast agglutination assay. Whereas non-treated
or DMSO-treated UTI89 showed an agglutination titre of 1:8,
AL1-treated cultures showed a lack of yeast agglutination within
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Figure 3. In vivo pilus biogenesis inhibition by AL1. (a) Inhibition of UTI89 type 1 pilus-dependent biofilm formation in the presence of AL1 and AL1*
(commercial and resynthesized, respectively) at various concentrations, plotted as the percentage of biofilm formation relative to the non-treated
UTI89. Data are presented as sample mean+SEM, n¼3. Curves show non-linear regression fits with a Hill slope of 21.4. UTI89 Dfim was deficient in
biofilm formation under the same static growth condition (Figure S4a, available as Supplementary data at JAC Online). (b) Abundance of
surface-exposed FimH on UTI89 grown in the presence of AL1 at 50 or 200 mM, as monitored by anti-FimH WCE and plotted as the percentage of
non-treated UTI89+SEM (n¼2, each carried out in triplicate). Statistical analysis was performed using two-tailed unpaired Student’s t-test to
compare the percentage of surface-exposed FimH of non-treated UTI89 with that of AL1-treated UTI89 at 50 and 200 mM (*P¼0.0004 and P¼0.0002,
respectively). (c) Representative electron micrographs of UTI89 grown in the presence of 50 or 200 mM AL1+1% DMSO, 1% DMSO and
non-supplemented LB (labelled UTI89). Additional representative electron micrographic images for each sample are in Figure S6, available as
Supplementary data at JAC Online.
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Figure 4. AL1 attenuates UTI89 bladder cell binding. Adherence of
AL1-treated (200 mM, 1% DMSO) UTI89 and UTI89 Dfim to human
urinary bladder epithelial cell line 5637. Data are expressed as
mean+SEM percentage adherence relative to non-treated UTI89; n¼2
independent experiments with three replicates each. Statistical analyses
were performed using two-tailed unpaired Student’s t-test to compare
the percentage of reduction in ability to bind to human bladder cells of
AL1-treated UTI89 with that of non-treated UTI89 (*P¼0.0003).
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Figure 6. AL1 activity against mature type 1 pili. Western blot analysis of type 1 pili in the presence of AL1. (a) DMSO or AL1 treatment of type 1 pili (i) or
negative control isolates (ii) obtained by MgCl2 precipitation of the supernatants of UTI89_LON and UTI89 Dfim, respectively. (iii) Purified FimC:FimH. (b)
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Curtailing bacterial virulence by pilus biogenesis inhibition
1023
JAC
 at Birkbeck College Library on June 11, 2014
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
1 min post-treatment (Figures 5c and S7, available as Supplemen-
tary data at JAC Online). These observations indicate that pre-
existing type 1 pili are lost from the bacterial surface upon addition
of AL1 and suggest that the compound retains an inhibitory effect
downstream of the FimH:FimG DSE reaction. To test whether AL1
disrupts pilus structure, type 1 pili isolated by heat extraction and
MgCl2 precipitation
38 were exposed to 200 and 500 mM compound.
SDS–PAGE analysis showed that FimH remained pilus-bound and
only migrated into the resolving gel when the samples were
boiled in 1% SDS (Figure 6a). Thus, AL1 does not affect quaternary
structure in preassembled pili. Chaperone–usher pili are tethered
to the bacterial surface by anchoring to the outer membrane
usher via the last incorporated chaperone:subunit complex.19
Possibly, AL1 binding to the basal subunit destabilizes the chap-
erone:subunit interaction, leading to the dissociation of the pili.
In support of this hypothesis, we found that, in contrast to
heat-extracted pili, type 1 pili found in the supernatant of an
AL1-treated bacterial suspension contained pilus-bound FimH,
but showed a drastically reduced stoichiometry of the FimC chap-
erone (Figure 6b and c).
Modelling of the putative AL1 binding site
In order to gain insight into the interaction of AL1 with the FimH
binding site, molecular docking was performed. A couple of low-
energy docking poses were suggested by the GOLD docking. Their
conformations, interactions in the binding pockets and GoldScore
were very similar. The best docking pose of AL1, based on Gold-
Score, is shown in Figure S8 (available as Supplementary data at
JAC Online). The structure of AL1 is quite flexible as it has many
rotatable bonds. However, in the docked structure it always
adopts a linear conformation, mimicking the N-terminus of FimG.
This conformation has a good shape that is complementary to
the binding pocket within FimH. There are two hydrogen bonds pro-
posed by this pose: one hydrogen bond is formed between the sul-
phonamide oxygen atom and the backbone NH of Ile115 while
another hydrogen bond is formed between the amide hydrogen
and the hydroxyl group of Tyr99. The various binding poses differed
in that AL1 shifts slightly along the pocket, maximizing the fit with
the binding site. The two hydrogen bonds may not be very strong.
In some poses theydid not form at all or in others, a different hydro-
gen bond was formed between another hydrogen donor or accept-
or within AL1 and a backbone NH or C¼O from another residue. It is
speculated that shape recognition and hydrophobic interactions
between AL1 and the protein are more important. However,
confirmation that AL1 indeed binds the FimH P5 area, and in
what conformation it does so, will require future structural valid-
ation. Thus far, attempts at co-crystallizing AL1 bound to the
chaperone:subunit complex have failed due to unfavourable
crystal-packing contacts in the P5 area.
The prophylactic and therapeutic advent of pilus
attenuation
The compound identified in this study represents a novel inhibitor
of type 1 pilus-mediated virulence in uropathogenic E. coli. The
concept of anti-virulence therapies has gained significant momen-
tum due to the increasing realization of the adverse effect of
broad-acting bacteriostatic or bacteriolytic antibiotics.4,14,45 Fur-
thermore, it is anticipated that targeted antibacterials could
minimize selective pressure that perpetuates drug resist-
ance.14,46,47 In UPEC-caused UTI, the rise in multiple antibiotic re-
sistance, the high incidence of recurrent infections and the high
burden of nosocomial UTIs, particularly in patients with urinary
catheters, provide a strong impetus for the development of alter-
native therapeutic and prophylactic treatments. In recent years,
potent receptor analogues that block binding of the FimH
adhesin to its high-mannose receptors on the host have been
developed.48 – 50 In vivo studies in a murine model of UPEC-caused
UTI have since shown that type 1 pilus virulence attenuation is a
viable therapeutic approach, reducing bacterial counts in the
affected organs to numbers similar to those seen after treatment
with commonly prescribed bacteriocidal or bacteriostatic antibio-
tics.51,52 This includes treatment of multidrug-resistant strains
such as the recently emerged pandemic UPEC strain ST131.9 More-
over, the bacterial clearance through virulence attenuation proved
synergistic with standard antibiotics.51 Besides type 1 pilus attenu-
ation via receptor analogues, efforts have been made towards the
development of pilus biogenesis inhibitors.53 A possible advantage
of biogenesis inhibitors compared with receptor analogues is their
use in the coating of urinary catheters in order to reduce the risk of
catheter-associated UTIs (CAUTIs). In contrast, adsorption of re-
ceptoranalogues on catheter walls risks attracting the attachment
of type-1-positive bacteria to urinary catheters.
Finally, fimbrial adhesins form important virulence factors in a
range of bacterial pathogens, most notably in human and
animal enteropathogens such as Shigella, Escherichiaand Salmon-
ella.54,55 For many of these fimbrial adhesins, however, inhibition
through receptor analogues promises to be problematic because
of the presence of an avidity-based adhesion mechanism (e.g.
polyadhesive binding with low affinity interactions—low micromo-
lar to millimolar—for the individual adhesin–glycan pairs) and/or
because of complex and shallow binding sites that show poor
druggability.4,14,45,56 In such cases, direct elimination of the orga-
nelles through inhibition of their biosynthetic step, as demon-
strated for the polymerization inhibitors identified in this study,
could provide a promising alternative approach.
In summary, we have demonstrated that specific screening
from in silico preselected compounds with predicted complemen-
tarity to the FimC:FimH donor strand acceptorgrooveyielded a spe-
cific inhibitor, AL1, that targeted the FimC:FimH DSE process.
Accordingly, AL1 was shown to inhibit type 1 pilus biogenesis
in vivo when added in low micromolar concentrations. Bacterial
cells treated with AL1 instantaneously and completely lost type 1
pili. To the best of our knowledge, AL1 is the first small compound
known to inhibit DSE. This study provides a basis for the further
design and development of anti-virulence drugs targeting the
DSE reaction mechanism, given its widespread conservation in
the chaperone–usher assembly of a diverse array of cell surface-
associated virulence determinants in many important bacterial
pathogens.
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